Cancer Treatment Reviews
Volume 29, Issue 5 , Pages 431-440 , October 2003

Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients

  • J Klastersky

      Affiliations

    • Corresponding Author InformationCorrespondence to: J. Klastersky M.D., Professor and Chief of Medicine, Department of Medicine, Institut Jules Bordet, Rue Héger-Bordet 1, 1000 Bruxelles, Belgium. Tel.: +32-25413201; fax: +32-25413202

References 

  1. Hughes WT, Armstrong D, Bodey GP, et al.  1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin. Infect. Dis. 1997;25:551–573
  2. Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J. Antimicrob. Chemother. 1998;41(Suppl D):13–24
  3. Oppenheim BA. The changing pattern of infection in neutropenic patients. J. Antimicrob. Chemother. 1998;41(Suppl D):7–11
  4. Jones RN, Low DE, Pfaller MA. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn. Microbiol. Infect. Dis. 1999;33:101–112
  5. Cometta A, Calandra T, Gaya H, et al.  Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob. Agents Chemother. 1996;40:1108–1115
  6. González-Barca E, Fernández-Sevilla A, Carratalá J, Granena A, Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur. J. Clin. Microbiol. Infect. Dis. 1996;15:291–296
  7. Pfaller MA, Jones RN, Doern GV, Kugler K and the SENTRY Participants Group. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998; 42: 1762–1770
  8. Elting LS, Rubenstein EB, Rolston KVI, Bodley GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin. Infect. Dis. 1997;25:247–259
  9. Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin. Infect. Dis. 1994;18:25–31
  10. Dugdale DC, Ramsey PG. Staphylococcus aureus bacteremia in patients with Hickman catheters. Am. J. Med. 1990;89:137–141
  11. Kiehn TE, Armstrong D. Changes in the spectrum of organisms causing bacteremia and fungemia in immunocompromised patients due to venous access devices. Eur. J. Clin. Microbiol. Infect. Dis. 1990;9:869–872
  12. Rubio M, Palau L, Vivas JR, et al.  Predominance of Gram-positive microorganisms as a cause of septicemia in patients with hematological malignancies. Infect. Control Hosp. Epidemiol. 1994;15:101–104
  13. Kibbler CC. Neutropenic infections: strategies for empiric therapy. J. Antimicrob. Chemother. 1995;36(Suppl B):107–117
  14. Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, Schentag JJ. Antimicrobial activity of quinupristin–dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn. Microbiol. Infect. Dis. 1998;30:437–451
  15. Schmitz F-J, Verhoef J, Fluit AC and the Sentry Participants Group. Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme. J Antimicrob Chemother 1999; 43: 783–792
  16. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin. Infect. Dis. 2000;30:454–460
  17. Gordon KA, Beach ML, Biedenbach DJ, Jones RN, Rhomberg PR, Mutnick AH. Antimicrobial susceptibility patterns of β-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997–2000). Diagn. Microbiol. Infect. Dis. 2002;43:157–162
  18. Lewis MT, Jones RN. Activity of macrolides, lincosamines, streptogramins and fluoroquinolones against Streptococcus pneumoniae and Enterococci isolates from the Western Hemisphere: example of International Surveillance (SENTRY Antimicrobial Surveillance Program) in the development of new drugs. Braz. J. Infect. Dis. 2000;4:15–21
  19. Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin. Infect. Dis. 1998;26:1179–1181
  20. Witte W. Antibiotic resistance in Gram-positive bacteria: epidemiological aspects. J. Antimicrob. Chemother. 1999;44(Topic A):1–9
  21. Von Eiff C, Reinert RR, Kresken M, Brauers J, Hafner D, Peters G. Nationwide German multicenter study on prevalence of antibiotic resistance in Staphylococcal bloodstream isolates and comparative in vitro activities of quinupristin–dalfopristin. J. Clin. Microbiol. 2000;38:2819–2823
  22. Marshall SA, Wilke WW, Pfaller MA, Jones RN. Staphylococcus aureus and coagulase-negative staphylococci from bloodstream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mec A) characterization of oxacillin resistance in the SCOPE Program. Diagn. Microbiol. Infect. Dis. 1998;30:205–214
  23. Archer GL, Climo MW. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob. Agents Chemother. 1994;38:2231–2237
  24. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob. Agents Chemother. 1996;40:891–894
  25. Evans PA, Norden CW, Rhoads S, Deobaldia J, Silber JL. In vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 1997;41:1406
  26. Tripodi MF, Attanasio V, Adinolfi LE, et al.  Prevalence of antibiotic resistance among clinical isolates of methicillin-resistant staphylococci. Eur. J. Clin. Microbiol. Infect. Dis. 1994;13:148–152
  27. Sieradzki K, Villari P, Tomasz A. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob. Agents Chemother. 1998;42:100–107
  28. Del’ Alamo L, Cereda RF, Tosin I, Miranda EA, Sader HS. Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides. Diagn. Microbiol. Infect. Dis. 1999;34:185–191
  29. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 1997;40:135–136
  30. Geisel R, Schmitz F-J, Thomas L, et al.  Emergence of heterogenous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Düsseldorf area. J. Antimicrob. Chemother. 1999;43:846–848
  31. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N. Engl. J. Med. 1999;340:517–523
  32. Smith TL, Pearson ML, Wilcox KR, et al.  Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med. 1999;340:493–501
  33. Tenover FC, Lancaster MV, Hill BC, et al.  Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 1998;36:1020–1027
  34. Noble WC, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol. Lett. 1992;93:195–198
  35. Daschner FD, Kropec A. Glycopeptides in the treatment of staphylococcal infections. Eur. J. Clin. Microbiol. Infect. Dis. 1995;14(Suppl 1):S12–S17
  36. Hamilton-Miller JMT, Shah S. Activity of quinupristin/dalfopristin against Staphylococcus epidermidis in biofilms: a comparison with ciprofloxacin. J. Antimicrob. Chemother. 1997;39(Suppl A):103–108
  37. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J. Antimicrob. Chemother. 1996;37:209–222
  38. Zeckel ML. A closer look at vancomycin, teicoplanin, and antimicrobial resistance. J. Chemother. 1997;9:311–335
  39. EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951–958
  40. Bryson HM, Spencer CM. Quinupristin–dalfopristin. Drugs. 1996;52:406–415
  41. Aumercier M, Bouhallab S, Capmau ML, Le Goffic F. RP 59500: a proposed mechanism for its bactericidal activity. J. Antimicrob. Chemother. 1992;30(Suppl A):9–14
  42. Cocito C, Di Giambattista M, Nyssen E, Vannuffel P. Inhibition of protein synthesis by streptogramins and related antibiotics. J. Antimicrob. Chemother. 1997;39(Suppl A):7–13
  43. Bouanchaud DH. In-vitro and in-vivo antibacterial activity of quinupristin–dalfopristin. J. Antimicrob. Chemother. 1997;39(Suppl A):15–21
  44. Dowzicky M, Nadler HL, Feger C, Talbot GH, Bompart F, Pease M. Evaluation of in vitro activity of quinupristin/dalfopristin (Q/D) and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. Am. J. Med. 1998;104(5A):34S–42S
  45. National Committee for Clinical Laboratory Standards (NCCLS). Subcommittee on Antimicrobial Susceptibility Testing. Minutes of June 1998 meeting. Reston, Villanova, USA
  46. Andrews J, Ashby J, Jevons G, Lines N, Wise R. Antimicrobial resistance in Gram-positive pathogens isolated in the UK between October 1996 and January 1997. J. Antimicrob. Chemother. 1999;43:689–698
  47. Cohen MA, Huband MD. Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Diagn. Microbiol. Infect. Dis. 1999;33:43–46
  48. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin. Infect. Dis. 2001;32:S133–S145
  49. Desnottes JF, Diallo N. Cellular uptake and intracellular bactericidal activity of RP 59500 in murine macrophages. J. Antimicrob. Chemother. 1992;30(Suppl A):107–115
  50. Berthaud N, Desnottes J-F. In-vitro bactericidal activity of quinupristin/dalfopristin against adherent Staphylococcus aureus. J. Antimicrob. Chemother. 1997;39(Suppl A):99–102
  51. Berthaud N, Huet Y, Diallo N, Desnottes JF. Antistaphylococcal activities of quinupristin/dalfopristin in vitro across platelet-fibrin matrices and in experimental endocarditis. J. Antimicrob. Chemother. 1997;39(Suppl A):93–98
  52. Fass RJ. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob. Agents Chemother. 1991;35:553–559
  53. Verbist L, Verhaegen J. Comparative in-vitro activity of RP 59500. J. Antimicrob. Chemother. 1992;30(Suppl A):39–44
  54. Hoban DJ, Weshnoweski B, Palatnick L, Zhanel CG, Davidson RJ. In-vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies. J. Antimicrob. Chemother. 1992;30(Suppl A):59–65
  55. Shonekan D, Handwerger S, Mildvan D. Comparative in-vitro activities of RP 59500 (quinupristin/dalfopristin), CL 329,998, Cl 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria. J. Antimicrob. Chemother. 1997;39:405–409
  56. Entenza JM, Drugeon H, Glauser MP, Moreillon P. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob. Agents Chemother. 1995;39:1419–1424
  57. Fantin B, Leclercq R, Merle Y, et al.  Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin–dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob. Agents Chemother. 1995;39:400–405
  58. Caron F, Gold HS, Wennersten CB, Farris MG, Moellering RC, Eliopoulos GM. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin–dalfopristin) against vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 1997;41:2749–2753
  59. Brumfitt W, Hamilton-Miller JMT, Shah S. In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against Gram-positive bacteria. J. Antimicrob. Chemother. 1992;30(Suppl A):29–37
  60. Neu HC, Chin N-X, Gu J-W. The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination. J. Antimicrob. Chemother. 1992;30(Suppl A):83–94
  61. Leclercq R, Nantas L, Soussy C-J, Duval J. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide, streptogramin antibiotics. J. Antimicrob. Chemother. 1992;30(Suppl A):67–75
  62. Low DE, Nadler HL. A review of in-vitro antibacterial activity of quinupristin–dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus. J. Antimicrob. Chemother. 1997;39(Suppl A):53–58
  63. Kostman JR, Fekete T, Woodwell J. Emergence of macrolide-streptogramin resistance during therapy of Staphylococcus aureus bacteremia with quinupristin/dalfopristin (RP59500). Clin. Infect. Dis. 1995;21:746; Abstract
  64. Chow JW, Donabedian SM, Zervos MJ. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Brief report. Clin. Infect. Dis. 1997;24:90–91
  65. Dowzicky M, Talbot GH, Feger C, Prokocimer P, Etienne J, Leclercq R. Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program. Diagn. Microbiol. Infect. Dis. 2000;37:57–62
  66. Fantin B, Leclercq R, Garry L, Carbon C. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin–dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrob. Agents Chemother. 1997;41:931–935
  67. Aeschlimann JR, Zervos MJ, Rybak MJ. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin–dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 1998;42:2710–2717
  68. Vouillamoz J, Entenza JM, Giddey M, Glauser MP, Moreillon P. In vitro efficacy of Synercid (quinupristin/dalfopristin) (SYN) combined with other classes of antibiotics against methicillin susceptible and resistant Staphylococcus aureus (MSSA and MRSA). Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 1996
  69. Vouillamoz J, Entenza JM, Giddey M, Glauser MP, Moreillon P. Synercid (SYN) alone or combined with cefepime (FEP) in the treatment (Rx) of experimental endocarditis (EE) due to methicillin-resistant Staphylococcus aureus (MRSA) resistant to macrolide-lincosamide-streptogramin B (MLSB-resistant). Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 1998
  70. Chin NX, Neu HC. Post-antibiotic effect of the new streptogramin RP 59500. Eur. J. Clin. Microbiol. Infect. Dis. 1992;11:642–645
  71. Boswell FJ, Andrews JM, Wise R. The postantibiotic effect of RP 59500 on Staphylococcus aureus including strains with a raised MBC. J. Antimicrob. Chemother. 1994;33:1219–1222
  72. Nougayrede A, Berthaud N, Bouanchaud DH. Postantibiotic effects of RP 59500 with Staphylococcus aureus. J. Antimicrob. Chemother. 1992;30(Suppl A):101–106
  73. Craig W, Ebert S. Pharmacodynamic activities of RP 59500 in an animal infection model. In: Program and Abstracts of the thirty-third Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, 17–20 October 1993. Abstract p. 205. American Society for Microbiology, Washington, DC
  74. Bergeron M, Montay G. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. J. Antimicrob. Chemother. 1997;39(Suppl A):129–138
  75. Rubinstein E, Prokocimer P, Talbot GH. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J. Antimicrob. Chemother. 1999;44(Topic A):37–46
  76. Chambers HF. Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 1992;30(Suppl A):117–122
  77. Fantin B, Leclercq R, Ottaviani M, et al.  In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob. Agents Chemother. 1994;38:432–437
  78. L’Hériteau F, Entenza JM, Lacassin F, Leport C, Glauser MP, Moreillon P. RP 59500 prophylaxis of experimental endocarditis due to erythromycin-susceptible and -resistant isogenic pairs of viridans group streptococci. Antimicrob. Agents Chemother. 1995;39:1425–1429
  79. Berthaud N, Montay G, Conard BJ, Desnottes JF. Bactericidal activity and kinetics of RP 59500 in a mouse model of Staphylococcus aureus septicemia. J. Antimicrob. Chemother. 1995;36:365–373
  80. Finch RG. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use. Drugs. 1996;51(Suppl 1):31–37
  81. Raad I, Bompart F, Hachem R. Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur. J. Clin. Microbiol. Infect. Dis. 1999;18:199–202
  82. Talbot GH, Barriere S, Cerwinka S, et al. Efficacy of quinupristin/dalfopristin (Synercid, RP 59500) in the treatment of patients with positive blood cultures in global phase III studies. In Abstracts/Posters Presented at the 20th International Congress of Chemotherapy (ICC), Sydney, Australia, June 29–July 3, 1997
  83. Nichols RL, Graham DR, Barriere SL, et al.  for the Synercid Skin and Skin Structure Infection Group. Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. J. Antimicrob. Chemother. 1999;44:263–273
  84. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH for the Synercid Emergency-Use Study Group. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1999; 44: 251–261
  85. Srinath L, Feger C, Richard M-P, Prokocimer P, Gray SL. Efficacy and safety of quinupristin/dalfopristin (Synercid) for treatment of methicillin-resistant Staphylococcus aureus infections. In Abstracts/Posters Presented at the 5th International Conference on the macrolides, azalides, streptogramins, ketolides and oxazolidinones (ICMAS-KO), Seville, Spain, January 26–28, 2000

PII: S0305-7372(03)00069-0

doi: 10.1016/S0305-7372(03)00069-0

Cancer Treatment Reviews
Volume 29, Issue 5 , Pages 431-440 , October 2003

Article Tools